Metabolic
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
Brand: MSUD Lophlex
PBAC's latest decision on Amino acid formula with vitamins and minerals without valine, leucine and isoleucine: Recommended with restriction (2020). Considered for Dietary management of Maple Syrup Urine Disease (MSUD).
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
2014 → 2020
Eligible population Patients aged 3 years or over with Maple Syrup Urine Disease requiring dietary management.
Therapy area Metabolic Line of therapy Not applicable Evidence base Cost-minimisation Primary endpoint Cost-minimisation Comparator MSUD Express 20, MSUD Cooler 20, MSUD Lophlex LQ 20, MSUD Maxamum Economic model Cost-minimisation ICER note Cost-minimisation analysis; no ICER calculated. Submission history Jul 2014 : Recommended with restriction · RestrictedNov 2014 : Deferred · RestrictedNov 2019 : Recommended with restriction · RestrictedJul 2020 : Recommended with restriction · RestrictedSimilar precedents Amino acid formula with vitamins and minerals without valine, leucine, isoleucine, supplemented with arachidonic acid and docosahexaenoic acid
similarity 0.92 Amino acid formula with fat, carbohydrate, without valine, leucine and isoleucine
similarity 0.86 Amino acid formula with vitamins and minerals (msud, tyr, hcu coolers)
similarity 0.76 Amino acid formula with vitamins and minerals (three formulations: without phenylalanine; without phenylalanine and tyrosine; without valine, leucine and isoleucine)
similarity 0.76 Amino acid formula (multiple formulations for pku, tyrosinaemia, ga1, mma/pa, hcu, msud)
similarity 0.72 Amino acid formula with vitamins and minerals, without phenylalanine
similarity 0.70 Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.